Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
出版年份 2020 全文链接
标题
Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
作者
关键词
-
出版物
Cancer Management and Research
Volume Volume 12, Issue -, Pages 8081-8091
出版商
Informa UK Limited
发表日期
2020-09-07
DOI
10.2147/cmar.s257482
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells
- (2019) Dongdong Luo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
- (2019) Oronzo Brunetti et al. Medicina-Lithuania
- Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway
- (2018) Mingxia Lu et al. BIOMEDICINE & PHARMACOTHERAPY
- Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway
- (2018) Jing Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death
- (2018) Wei Zheng et al. BIOMEDICINE & PHARMACOTHERAPY
- phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
- (2018) Cun Wang et al. JOURNAL OF HEPATOLOGY
- Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell CarcinomaIn Vitroand Patient-Derived XenograftsIn Vivo
- (2018) Mengqiu Song et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells
- (2018) Chien-Ming Chiu et al. OncoTargets and Therapy
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oridonin Enhances Radiation-Induced Cell Death by Promoting DNA Damage in Non-Small Cell Lung Cancer Cells
- (2018) Hyejin Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
- (2018) Young-Seon Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
- (2018) Wenliang Tan et al. EBioMedicine
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
- (2017) Andrea Casadei Gardini et al. EUROPEAN JOURNAL OF CANCER
- Laparoscopic liver re-resection is feasible for patients with posthepatectomy hepatocellular carcinoma recurrence: a propensity score matching study
- (2017) Kairui Liu et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- (2017) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Mitochondrial ROS contribute to oridonin-induced HepG2 apoptosis through PARP activation
- (2017) Xiaoning Liu et al. Oncology Letters
- Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition
- (2017) Li-Wen Rong et al. Oncology Letters
- Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells
- (2016) Xinjun Dong et al. ANTI-CANCER DRUGS
- Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor
- (2016) Chang-Hao Wu et al. JOURNAL OF SURGICAL RESEARCH
- Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress
- (2015) Bo Zhai et al. PLoS One
- Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
- (2014) Thuy V. Nguyen et al. BIOMATERIALS
- ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells
- (2014) GA BIN PARK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells
- (2012) Dahong Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
- (2011) F. van Zijl et al. MOLECULAR CANCER THERAPEUTICS
- Proteomic and Functional Analyses Reveal the Potential Involvement of Endoplasmic Reticulum Stress and α-CP1 in the Anticancer Activities of Oridonin in HepG2 Cells
- (2010) Hui Wang et al. INTEGRATIVE CANCER THERAPIES
- Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells
- (2010) Hui Wang et al. PHYTOMEDICINE
- Ent-Kaurane Diterpenoids fromRabdosia rubescensand Their Cytotoxic Effects on Human Cancer Cell Lines
- (2009) Naisheng Bai et al. PLANTA MEDICA
- Reactive Oxygen Species Mediate Oridonin-Induced HepG2 Apoptosis Through p53, MAPK, and Mitochondrial Signaling Pathways
- (2008) Jian Huang et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started